UBIO:NSD-ProShares UltraPro Nasdaq Biotechnology (USD)

ETF | Trading--Leveraged Equity | NSD

Last Closing Price

USD 17.77

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.03M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the NASDAQ Biotechnology Index® (the index). The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Valuation Growth & Performance

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-07 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Mer Price(Change) Market Cap
TQQQ ProShares UltraPro QQQ 0.95 %

N/A

USD10.30B
BIB ProShares Ultra Nasdaq Biotech.. 0.95 %

N/A

USD0.24B

ETFs Containing UBIO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Trading--Leveraged Equity)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -39.74% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.74% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -26.04% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.04% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.08% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.08% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.67% N/A N/A N/A N/A
Risk Adjusted Return -9.42% N/A N/A N/A N/A
Market Capitalization 0.02B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike